

### REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and following remarks.

Claim 13 has been amended to remove the limitation "and having no cholinesterase activity".

Thus, the rejection of the claims under 35 USC 112, first paragraph, as containing new matter is deemed to be overcome.

The objection to claim 13 is deemed to be overcome in view of the removal of the above limitation.

In the rejection, the Examiner indicated that the previous art rejections over the full length acetylcholinesterase have been withdrawn based upon the negative limitation, however that it would appear that the art rejection may be reinstated upon cancellation of the new matter from the claim. This position is respectfully traversed.

Claim 13 clearly defines over the full length acetylcholinesterase. The full length enzyme has over 500 amino acids. The isolated peptide according to (b) of the claim could not encompass the full length enzyme, since the isolated peptide must have "at least 70% homology with the peptide of SEQ ID No. 1". The full length enzyme having in excess of 500 amino acids could not have at least 70% homology with the 14 amino acid peptide of SEQ ID No. 1.

In view of the foregoing, it is believed that each ground of rejection set forth in the Action have been overcome, and that the application is now in condition for allowance. Accordingly, such allowance is solicited.

Regarding the Examiner's question about the palm system, no affidavit or other exhibit was submitted on October 8, 2003.

Respectfully submitted,

Susan A. GREENFIELD et al.

By: Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
March 3, 2004